Calprotectin Testing Market Size, Share & Trends Analysis Report By Sample Type (Fecal Calprotectin, Serum and Plasma Calprotectin, Other Samples), By Assay Technology (Enzyme-Linked Immunosorbent Assay, ELISA, Immunoturbidimetric Assay, Chemiluminescent Immunoassay, Other Immunoassays), By Testing Format (Laboratory-Based Testing, Point-of-Care Testing, Others), By Application (Inflammatory Bowel Disease Diagnosis and Differentiation, Inflammatory Bowel Disease Monitoring, Other Applications), By End User (Diagnostic Laboratories, Hospitals and Specialty Clinics, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

 Calprotectin Testing Market Size & Share Analysis

The global calprotectin testing market size was valued at USD 500.00 million in 2025 and is projected to grow from USD 551.00 million in 2026 to USD 1198.41 million by 2034, registering a CAGR of 10.20% during the forecast period (2026-2034). North America dominated the calprotectin testing market  with a share of 41.5% in 2025.

Calprotectin testing involves diagnostic tests used to measure calprotectin levels in stool samples to identify intestinal inflammation and support the diagnosis and monitoring of inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.  Calprotectin testing products are tracked under HSN Code 3822 (diagnostic or laboratory reagents and prepared diagnostic reagents) and SIC Code 8071 (medical laboratories).

The calprotectin testing market demand is driven by the preference for non-invasive diagnostic methods and a focus on early detection and monitoring of intestinal inflammation. Healthcare providers and diagnostic laboratories are adopting stool-based calprotectin tests to distinguish inflammatory bowel conditions from non-inflammatory gastrointestinal disorders.

Calprotectin Testing Market Segmentation Analysis

By Sample Type

Fecal calprotectin segment accounted for a dominant share of 82.5% in 2025, supported by its widespread use as a non-invasive biomarker for detecting intestinal inflammation and evaluating inflammatory bowel diseases. The use of fecal calprotectin testing to distinguish inflammatory conditions from functional gastrointestinal disorders and monitor treatment response continues to support the segment’s position in the calprotectin testing market.

The serum and plasma calprotectin segment is expected to grow at a CAGR of 9.5% during the forecast period, driven by the increasing use of blood-based biomarkers to assess systemic inflammation and support the evaluation of inflammatory conditions.

Request Customizationto receive a tailored report.

By Assay Technology

ELISA held a 35.5% share of the assay technology segment in 2025 due to its suitability for measuring calprotectin concentrations in clinical samples and identifying inflammation associated with gastrointestinal disorders. Its compatibility with routine laboratory workflows and ability to process multiple patient samples support its continued use in inflammatory bowel disease assessment.

Lateral flow immunoassay is projected to grow at a CAGR of 12.2% during the forecast period, propelled by the need for rapid calprotectin assessment and simpler testing procedures outside conventional laboratory environments. 

By Testing Format

Laboratory-based testing represented 73.5% of the calprotectin testing market in 2025, reflecting the continued reliance on centralized diagnostic facilities for standardized sample processing and quantitative calprotectin measurement. Established laboratory infrastructure, trained personnel, and access to ELISA-based testing systems support the use of these services for inflammatory bowel disease diagnosis.

Home self-testing is anticipated to record a growth rate of 14.2% during the forecast period, fueled by the preference for convenient testing options that reduce dependence on laboratory visits. The availability of at-home sample collection kits and simplified testing procedures is expected to expand access to calprotectin monitoring.

By Application

Inflammatory bowel disease diagnosis and differentiation accounted for 43.5% of the application segment in 2025, reflecting the importance of distinguishing inflammatory bowel diseases from non-inflammatory gastrointestinal disorders. Fecal calprotectin measurements help clinicians assess intestinal inflammation and determine the need for further diagnostic investigations.

The inflammatory bowel disease monitoring segment is likely to witness a CAGR of 11.2% during the forecast period, as patients with Crohn’s disease and ulcerative colitis require repeated assessments to track disease activity and treatment response. 

By End User

Diagnostic laboratories held a 45.5% share of the calprotectin testing market in 2025, supported by their role in processing stool samples and delivering quantitative results for gastrointestinal disease evaluation.

Home users will expand to 14.5% CAGR during the forecast period, driven by the need for easier access to routine calprotectin assessments without repeated visits to healthcare facilities.

Speak to an Analystto discuss market opportunities.

Calprotectin Testing Market Regional Analysis

North America Calprotectin Testing Market

North America's calprotectin testing market accounted for a dominant share of 41.5% in 2025.

U.S. Calprotectin Testing Market

The American Gastroenterological Association recommends stool-based biomarkers, including fecal calprotectin, alongside clinical evaluation and other diagnostic procedures to monitor Crohn’s disease. These tests can help assess intestinal inflammation and determine when further evaluation, including endoscopy, may be needed. A fecal calprotectin assay from BÜHLMANN Laboratories was added to the U.S. FDA’s Clinical Laboratory Improvement Amendments (CLIA) database for use with Roche’s cobas c 703 analyzer.

Canada Calprotectin Testing Market

Canadian diagnostic laboratories use fecal calprotectin testing to support the assessment of suspected inflammatory bowel disease and distinguish intestinal inflammation from non-inflammatory gastrointestinal conditions. The growing role of this non-invasive biomarker in clinical evaluation and treatment monitoring supports demand for calprotectin assay kits and reagents across Canadian healthcare facilities.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Calprotectin Testing Market

The Asia Pacific calprotectin testing market will expand at a CAGR of 12.2%, showcasing the fastest-growing regional market.

Japan Calprotectin Testing Market

Japan’s Ministry of Health, Labour and Welfare includes fecal calprotectin testing in its national medical fee schedule at 268 points. The test can support the diagnosis of suspected chronic IBD, including ulcerative colitis and Crohn’s disease, under specified clinical conditions, and can be used to monitor disease activity. This established reimbursement pathway creates a viable environment for diagnostic manufacturers and clinical laboratories supplying fecal calprotectin assays using ELISA, fluorescence enzyme immunoassay, and latex agglutination methods.

China Calprotectin Testing Market

Chinese diagnostic laboratories continued to expand the use of automated fecal calprotectin testing systems compatible with routine biochemical analyzers. These systems streamline sample processing and reduce manual laboratory work, supporting wider adoption of calprotectin testing for assessing intestinal inflammation and monitoring inflammatory bowel disease across hospitals and diagnostic facilities.

India Calprotectin Testing Market

Indian diagnostic providers continued to expand access to non-invasive fecal calprotectin testing for evaluating intestinal inflammation and supporting inflammatory bowel disease management. The adoption of these tests across hospitals and diagnostic laboratories supports demand for calprotectin assay kits and reagents, while point-of-care testing solutions offer opportunities to improve access to timely clinical assessment and treatment monitoring for patients with Crohn’s disease and ulcerative colitis.

Europe Calprotectin Testing Market

Europe's calprotectin testing market is anticipated to grow at a CAGR of 9.7% during the forecast period.

U.K. Calprotectin Testing Market

Barking, Havering and Redbridge University Hospitals NHS Trust introduced a green-top sample tube that allows faecal calprotectin and faecal immunochemical testing (FIT) to be performed from a single sample. This change supports more efficient sample collection and laboratory workflows, strengthening the adoption of calprotectin testing services across UK healthcare facilities.

Germany Calprotectin Testing Market

The Central Laboratory at University Medical Center Mainz added serum calprotectin testing to its laboratory ordering system, expanding access to this biomarker for clinical assessment. Separately, Germany’s established diagnostic laboratories continue to use fecal calprotectin testing to support inflammatory bowel disease diagnosis and treatment monitoring, sustaining demand for diagnostic assays and laboratory testing services.

Latin America Calprotectin Testing Market

The Latin America calprotectin testing market is expected to grow at a CAGR of 10.8% during the forecast period. Mexico’s calprotectin testing market serves the clinical need for non-invasive assessment of intestinal inflammation in patients with inflammatory bowel disease. A study published in F1000Research, Patient Knowledge of Fecal Calprotectin in Inflammatory Bowel Disease examined patient awareness of the test and its role in disease management. Pontifical Catholic University of Brzail tudied fecal calprotectin as a tool to distinguish inflammatory bowel diseases from conditions such as irritable bowel syndrome. This clinical application supports the use of calprotectin tests in Brazilian gastroenterology services for disease assessment and treatment monitoring.

Middle East & Africa Calprotectin Testing Market

The Middle East & Africa calprotectin testing market is expected to grow at a CAGR of 10.5% during the forecast period. National Reference Laboratory provides fecal calprotectin testing in the UAE using particle-enhanced turbidimetric immunoassay to support the assessment of intestinal inflammation. Diagnostic providers such as DNA Labs Africa offers fecal calprotectin testing in South Africa to help clinicians evaluate inflammatory bowel disease and other gastrointestinal conditions.

Competitive Landscape

The calprotectin testing market competitive landscape includes established diagnostic companies, clinical laboratory solution providers, and specialized immunoassay manufacturers. Key players such as BÜHLMANN, R-Biopharm, DiaSorin, and Calpro  are estimated to account for 30–40% of the global calprotectin testing market share.

Established players compete through test accuracy, assay reliability, diagnostic consistency, and compatibility with laboratory workflows. Emerging players in calprotectin testing market ecosystem focus on stool calprotectin assays, automated testing platforms, and diagnostic kits.

List of Key and Emerging Players in Calprotectin Testing Market